retatrutide type 2 diabetes trial results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 New Kind of Diabetes Drug

For the forty-three percent planning to offer coverage next year, we recommend a physician-led approach that guides who should be prescribed GLP-1 medications and how to make them part of a holistic health management plan." Survey Key Findings Trusted information and cost are barriers The main obstacles to incorporating GLP-1 medications are lack of trusted information and the perceived high cost associated with them

Summary: GLP-1 receptor agonists do not directly cause sweating, but some patients report changes in perspiration patterns due to indirect factors such as gastrointestinal side effects, hypoglycaemia when combined with other diabetes medications, or autonomic responses to nausea

Safety Backed by Research The safety of GLP-1 medications is well-supported by extensive research

Research highlights that a small percentage of women taking semaglutide experience menstrual changes

While its effects are temporary, regular treatments can help maintain optimal levels, allowing your body to continuously benefit from its detoxifying and antioxidative properties

I have called both the doctors office and the pharmacy multiple times